TNF-α and Tumor Lysate Promote the Maturation of Dendritic Cells for Immunotherapy for Advanced Malignant Bone and Soft Tissue Tumors

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Miwa, Shinji ^a   Nishida, Hideji ^a   Tanzawa, Yoshikazu ^a   Takata, Munetomo ^a   Takeuchi, Akihiko ^a   Yamamoto, Norio ^a   Shirai, Toshiharu ^a   Hayashi, Katsuhiro ^a   Kimura, Hiroaki ^a   Igarashi, Kentaro ^a   Mizukoshi, Eishiro ^a   Nakamoto, Yasunari ^a   Kaneko, Shuichi ^a   Tsuchiya, Hiroyuki ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4; PICIBANIL; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; BONE CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL LYSATE; CELL MATURATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECURRENT CANCER; SCHOOL CHILD; SOFT TISSUE TUMOR; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CELL DIFFERENTIATION; CHILD; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-4; MALE; MIDDLE AGED; PICIBANIL; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871386881     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052926     Document Type: Article

References (38)

1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
2. Palucka K, Banchereau J, (1999) Dendritic cells: a link between innate and adaptive immunity. J Clin Immunol 19: 12-25.
3. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C, (2001) Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22: 41-47.
4. Gregoire M, Ligeza-Poisson C, Juge-Morineau N, Spisek R, (2003) Anticancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 21: 791-794.
5. Villadangos JA, Schnorrer P, Wilson NS, (2005) Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol Rev 207: 191-205.
6. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ, (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10: 475-480.
7. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Hermine O, Tough DF, et al. (2005) Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol 175: 15-20.
8. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ, (2005) Intratumoral immunotherapy: using the tumour against itself. Immunology 114: 11-22.
9. Sanchez-Sanchez N, Riol-Blanco L, Rodriguez-Fernandez JL, (2006) The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J Immunol 176: 5153-5159.
10. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58.
11. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332.
12. Steinman RM, Banchereau J, (2007) Taking dendritic cells into medicine. Nature 449: 419-426.
13. Joyama S, Naka N, Tsukamoto Y, Yoshikawa H, Itoh K, (2006) Dendritic cell immunotherapy is effective for lung metastasis from murine osteosarcoma. Clin Orthop Relat Res 453: 318-327.
14. Kawano M, Nishida H, Nakamoto Y, Tsumura H, Tsuchiya H, (2010) Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma. Clin Orthop Relat Res 468: 1373-1383.
15. Dauer M, Obermaier B, Herten J, Haerle C, Pohi K, et al. (2003) Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 15: 4069-4076.
16. Li YP, Paczesny S, Lauret E, Poirault S, Bordigoni P, et al. (2008) Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 180: 1598-1608.
17. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-780.
18. Steinman RM, Hawiger D, Nussenzweig MC, (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711.
19. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, et al. (1999) Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104: 173-180.
20. Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N, (1997) A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90: 3640-3646.
21. Grimer RJ, (2005) Surgical options for children with osteosarcoma. Lancet Oncol 6: 85-92.
22. Dougan M, Dranoff G, (2009) Immune therapy for cancer. Annu Rev Immunol 27: 83-117.
23. Ribas A, Butterfield LH, Glaspy JA, Economou JS, (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21: 2415-2432.
24. Wertel I, Polak G, Bednarek W, Barczynski B, Rolinski J, et al. (2008) Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom 74: 251-258.
25. Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y, Kitahara M, et al. (2007) Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 147: 296-305.
26. Okamoto H, Shoin S, Koshimura S, Shimizu R, (1967) Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 11: 323-326.
27. Hovden AO, Karlsen M, Jonsson R, Aarstad HJ, Appel S, (2011) Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses. BMC Immunol 12: 2.
28. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, et al. (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32.
29. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, et al. (2003) Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104: 92-97.
30. Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, et al. (2007) Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes in fltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56: 1459-1469.
31. Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, et al. (2009) Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 15: 3563-3569.
32. Matsumoto M, Seya T, Kikkawa S, Tsuji S, Shida K, et al. (2001) Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol 1: 1559-1569.
33. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, et al. (2007) Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Translat Med 5: 67.
34. Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JL, et al. (2005) Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 90: 97-104.
35. Agarwal A, Agrawal U, Verma S, Mohanty NK, Saxena S, (2010) Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacology Immunotoxicol 32: 348-356.
36. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, et al. (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089-3094.
37. Tsuboi K, Miyazaki T, Nakajima M, Fukai Y, Masuda N, et al. (2004) Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett 18: 207-214.
38. Moretti S, Chiarugi A, Semplici F, Salvi A, De Giorgi V, et al. (2001) Serum imbalance of cytokines in melanoma patients. Melanoma Res 11: 395-399.